BioCentury
ARTICLE | Company News

Tris Pharma, Vernalis Group deal

August 18, 2014 7:00 AM UTC

The partners said Tris achieved a milestone under a February 2012 deal granting Vernalis exclusive, North American rights to commercialize up to six reformulated prescription cough and cold products using Tris’ OralXR+ extended-release formulation technology. The milestone was triggered by Tris’ achievement of proof of concept for CCP-08. The compound is an extended-release formulation of an undisclosed existing cough and cold product. The partners said that proof of concept includes the completion of a human pilot study comparing CCP-08 to an immediate-release reference product. The companies could not be reached for details. ...